NCT02876224View on ClinicalTrials.gov

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

June 25, 2019

Study Completion Date

June 25, 2019

Conditions
Colorectal Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

DRUG

Bevacizumab

Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.

DRUG

Cobimetinib

Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.

Trial Locations (6)

10065

Memorial Sloan-Kettering Cancer Center, New York

28050

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid

37203

Sarah Cannon Research Inst., Nashville

80045

University Of Colorado, Aurora

77030-4009

The University of Texas MD Anderson Cancer Center, Houston

08035

Hospital Universitario Vall d'Hebron, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | Biotech Hunter | Biotech Hunter